ERYP Erytech Pharma S.A.

-0.65  -8%
Previous Close 8.24
Open 8.21
Price To Book 0.83
Market Cap 136164600
Shares 17,940,000
Volume 5,540
Short Ratio
Av. Daily Volume 2,321

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial completed.
Phase 3 enrollment to commenced soon - noted September 10, 2018.
Eryaspase (GRASPA)
Pancreatic cancer
Upcoming meeting with FDA to discuss next steps.
Eryaspase (GRASPA)
Acute lymphoblastic leukemia (ALL) - front line
Phase 2 enrolment to commence 2Q 2019.
Eryaspase (GRASPA)
Triple-Negative Breast Cancer (TNBC)
Phase 2b planned for 1H 2019.
Eryaspase (GRASPA)
Pancreatic cancer - first-line